C-reactive protein (CRP) in serum/plasma high-sensitivity
Jump to navigation
Jump to search
Indications
American Heart Association & CDC guidelines
- no general agreement regarding cost-effectiveness
- optional CRP testing endorsed
- patient with intermediate risk
- marker of prognosis after coronary angiography &/or PTCA
- outcome data using high-sensitivy CRP not available
- optional CRP testing may be considered
- global risk assessment for adults without known cardiovascular disease
- motivation for patients to improve lifestyle behaviors
- selection of at risk patients for statin therapy (see Jupiter study)*[4]
* Indication(s) controversial
Clinical significance
- levels < 1.0 mg/L consistent with low cardiovascular risk
- levels > 3.0 mg/L consistent with high cardiovascular risk Procredure:
- use average of 2 measurements; 2 weeks apart
- a single measurement is appropriate if < 1.0 mg/L[3]
Methods
- Immunochemiluminometric Assay (ICMA)
- method able to detect 0.03 mg/L of CRP
More general terms
References
- ↑ Journal Watch 24(1):2, 2004 Pearson TA et al Circulation 107:499, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12551878
- ↑ Journal Watch 23(8):68, 2003
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 4.0 4.1 Ridker PM, Danielson E, Fonseca FA Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18997196